Akums Drugs and Pharmaceuticals Limited (NSE: AKUMS, BSE: 544222) is a Delhi-based company in the Domestic contract manufacturers industry. With a market capitalisation of ₹11,787 Cr, it ranks #547 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 4 in Domestic contract manufacturers. At ₹713.00 (as of 19 Nov 2026), the share price is 15.0% below its 52-week high of ₹838.80 and 74.2% above its 52-week low of ₹409.30. The share price is up 57.3% over one year and down 5.3% over three months.
| Current Price | ₹713.00 |
|---|---|
| Market Cap | ₹11,787 Cr |
| NSE Symbol | AKUMS |
| BSE Code | 544222 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Domestic contract manufacturers |
| P/E Ratio | 45 |
| Return on Equity | 8.02% |
| Return on Assets | 4.84% |
| 52-Week Range | ₹409.30 – ₹838.80 |
| 1-Year Price Change | +57.3% |
| 3-Month Price Change | -5.3% |
| Beta (1Y) | 0.31 |
| Dividend Yield | 0.13% |
| Headquarters | Delhi |
| Website | www.akums.in |
| Revenue | ₹1,342 Cr |
|---|---|
| Net Profit | ₹115 Cr |
| Net Margin | 8.5% |
| EPS (Basic) | ₹7.37 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Akums Drugs and Pharmaceuticals Limited reported revenue of ₹1,342 Cr in Q2 FY27, up 31.9% from ₹1,018 Cr in Q2 FY26 and up 15.1% from ₹1,167 Cr in Q1 FY27. It posted a net profit of ₹115 Cr for the quarter, against a net profit of ₹43 Cr in Q2 FY26 (up 168.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1,018 Cr (Q2 FY26) to ₹1,342 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹1,342 Cr | ₹115 Cr | 8.5% |
| Q1 FY27 | ₹1,167 Cr | ₹101 Cr | 8.7% |
| Q4 FY26 | ₹1,158 Cr | ₹81 Cr | 7.0% |
| Q3 FY26 | ₹1,160 Cr | ₹68 Cr | 5.8% |
| Q2 FY26 | ₹1,018 Cr | ₹43 Cr | 4.2% |
| Q1 FY26 | ₹1,024 Cr | ₹65 Cr | 6.3% |
| Q4 FY25 | ₹1,056 Cr | ₹150 Cr | 14.2% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 75.26% of Akums Drugs and Pharmaceuticals Limited's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 46.8% of traded volume across 18 NSE sessions (26 Oct 2026 – 19 Nov 2026).
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, hard and soft gelatin capsules, liquid orals, sachets, vials, ampoules, form-fill-seal products, topical preparations, eye drops, dry powder injections, and gummies for therapeutic areas, such as antiinfectives, pain management, gastroenterology, orthopaedics, cardio-diabetic care, critical care, respiratory, and gynaecology. In addition, the company operates as pharmaceutical contract development and manufacturing company. Akums Drugs and Pharmaceuticals Limited was incorporated in 2004 and is based in Delhi, India.
1. CDMO-This segment engages in the research and development, preparation and regulatory filing of dossiers; manufacturing formulations on contract basis and job work; and provides testing services. 2. API-This segment engages in the manufacture and sale of active pharmaceutical ingredient products. 3. Domestic Branded Formulations-This segment engages in the marketing of branded pharmaceutical formulations. 4. International Branded Formulations-This segment engages in the marketing of pharmaceutical formulations.
1. CDMO-85.1% 2. API-5.3% 3. Domestic Branded Formulations-10.2% 4. International Branded Formulations-3.3% 5. #PEND-2.3%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Akums Drugs and Pharmaceuticals Limited | ₹11,787 Cr | 45 | 8.02% | ₹1,342 Cr | +57.3% |
| INNOVA CAPTAB LIMITED | ₹6,249 Cr | 47.3 | 14.03% | ₹496 Cr | +37.2% |
| Windlas Biotech Ltd | ₹2,060 Cr | 32.6 | 12.23% | ₹264 Cr | +18.9% |
| Influx Healthtech Limited | ₹588 Cr | 28.7 | 20.39% | — | — |
Listed by market capitalisation. Ratios are shown for context only.
Akums Drugs and Pharmaceuticals Limited is trading at ₹713.00, with a market capitalisation of ₹11,787 Cr.
Akums Drugs and Pharmaceuticals Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Domestic contract manufacturers).
Akums Drugs and Pharmaceuticals Limited has a P/E of 45 and a return on equity of 8.02%.
Akums Drugs and Pharmaceuticals Limited is listed on the NSE under the symbol AKUMS and on the BSE under the scrip code 544222.
Akums Drugs and Pharmaceuticals Limited's share price is up 57.3% over one year and down 5.3% over three months. Its 52-week range is ₹409.30 to ₹838.80.
In Q2 FY27, Akums Drugs and Pharmaceuticals Limited reported revenue of ₹1,342 Cr and net profit of ₹115 Cr, with basic EPS of ₹7.37 (consolidated, parsed from the company's exchange filing).
Akums Drugs and Pharmaceuticals Limited reported revenue of ₹1,342 Cr in Q2 FY27, up 31.9% from ₹1,018 Cr in Q2 FY26 and up 15.1% from ₹1,167 Cr in Q1 FY27.
Promoters held 75.26% of Akums Drugs and Pharmaceuticals Limited's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 19 Nov 2026. Descriptive market data only — not investment advice.